Clinical Trials Browser

Observational × disitamab vedotin × 90 days × Clear all

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Not yet recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma